Description
The global blood testing market, valued at $89.5 billion in 2025, is projected to reach $147.5 billion by 2032, growing at a CAGR of 7.4 percent. Growth is fuelled by structural shifts in disease burden, healthcare investment, and diagnostic expectations.
Chronic diseases remain the primary demand driver. Cardiovascular conditions, cancer, diabetes, and respiratory illnesses require continuous monitoring, early detection, and therapy optimization, placing blood diagnostics at the centre of clinical decision making. According to the World Health Organization, noncommunicable diseases caused 43 million deaths in 2021, representing 75 percent of non-pandemic mortality. Nearly three-quarters of these deaths occur in low- and middle-income countries, where healthcare systems are rapidly scaling diagnostic capacity.
As disease prevalence rises, providers are investing in advanced analyzers, automation platforms, and high-throughput laboratory infrastructure. Demand for consumables, including reagents and test kits, is increasing in parallel, driven by the need for accuracy, faster turnaround times, and regulatory compliance.
At the same time, rising healthcare expenditure and supportive public policy are reinforcing market momentum. Governments are expanding reimbursement coverage, funding preventive care initiatives, and promoting routine screening. Together, these factors are accelerating adoption across hospitals, diagnostic laboratories, and point-of-care settings, positioning blood testing as a foundational component of modern healthcare delivery.
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
